Compare Mattel Inc (MAT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs TransMedics Group Inc — how do they compare? Mattel Inc trades at $15 (market cap $4.30B), while TransMedics Group Inc trades at $87.35 (market cap $3.10B). The key difference: Mattel Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| MAT | TMDX | |
|---|---|---|
Market Cap | $4.30B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $22.16 | $150.42 |
52-Week Low | $13.05 | $61.99 |
Enterprise Value | $6.52B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $15.03, up 1.97% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, with a 10% revenue beat but an earnings miss due to higher costs. Valuation ratios appear reasonable with a P/E of 11.22 and P/S of 0.84. Analyst consensus is a 'Hold' with a $14.00 price target, slightly below the current price. Recent news highlights growth from toy-based movies and adult collectors, though profit margins face pressure from advertising and SG&A expenses.
The outlook for Mattel is cautiously optimistic, driven by IP expansion and brand strength, but near-term risks include cost inflation and discretionary spending headwinds. Investment opportunity lies in execution of entertainment strategy, while key risks are margin compression and competitive pressures. The stock's current level near analyst targets suggests limited upside without improved earnings momentum.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
